Biotechnology News and Research

RSS

MBL generates human monoclonal antibodies against pandemic A type influenza virus

Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

27 Jan 2010

Helicos BioSciences adds new sequencing kits and run configurations for its Genetic Analysis System

Helicos BioSciences Corporation announced today the introduction of a series of new single molecule sequencing kits and run configurations for the Helicos® Genetic Analysis System that will expand its versatility for customers. These new products and configurations, available without any System hardware upgrades, offer customers the ability to tailor parameters of the System to the specific application and number of samples under study.

27 Jan 2010

Burnham renamed to honor T. Denny Sanford's support

Burnham Institute for Medical Research (Burnham) announced today that philanthropist T. Denny Sanford has pledged $50 million to support and further expand and accelerate the Institute's leading-edge medical research. To honor Sanford, Burnham, has been renamed the Sanford-Burnham Medical Research Institute. This is the second gift Sanford has made to Burnham. In 2007, he directed $20 million through Sanford Health to create the Sanford Children's Health Research Center at Burnham.

27 Jan 2010

U.S. court decision favors Teva in generic Temodar ANDA litigation

Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Delaware has issued a decision in its litigation over the Company's Abbreviated New Drug Application (ANDA) to market its generic version of Schering-Plough’s brain tumor treatment Temodar® (temozolomide). The Court found that U.S. Patent No. 5,260,291 is not enforceable due to prosecution laches and inequitable conduct.

27 Jan 2010

Microbia's beta-carotene receives 'GRAS' status for food and beverage applications

Microbia, Inc., today announced that a panel of independent experts has determined its bio-based β-carotene (beta-carotene) to be GRAS (Generally Recognized As Safe) for both food and beverage applications.

27 Jan 2010

UF researchers work out to find new treatments for Pompe disease

As scientists work to find new treatments for Pompe disease - the devastating genetic "villain" that drives the efforts of the main characters in the new film "Extraordinary Measures" - University of Florida researchers are hopeful that gene therapy will help patients in the late stages of the disease breathe on their own.

27 Jan 2010

MDRNA granted Chinese patent for use of nucleic acids in cancer treatment

MDRNA, Inc., a leading RNAi-based drug discovery and development company, today announced that the State Intellectual Property Office of the People's Republic of China (PRC) has issued a Notification of Granting Patent Rights for PRC 200480018784 which includes the use of nucleic acids, e.g., an siRNA, for the treatment of cancer. The patent describes modulation of claudins, which are proteins implicated in tumor progression and metastasis.

27 Jan 2010

Pfizer becomes the latest customer of Benchware Discovery 360

Tripos®, a leading provider of drug discovery informatics products and services, today announced that Pfizer has become the latest customer of Benchware® Discovery 360 (D360). The novel license agreement allows Pfizer to deploy the capabilities of D360 to all scientists within its worldwide research sites.

27 Jan 2010

UCF researcher develops first dual vaccine to fight malaria and cholera

A University of Central Florida biomedical researcher has developed what promises to be the first low-cost dual vaccine against malaria and cholera.

27 Jan 2010

Idaho Technology commences clinical trials of FilmArray RP

Idaho Technology, Inc. (ITI) announced today that clinical trials of the FilmArray Respiratory Panel (RP) have commenced at three US Hospital Laboratories.

27 Jan 2010

Fluxion Biosciences expands its IonFlux automated patch clamp system

Fluxion Biosciences announced today a product expansion for its IonFlux automated patch clamp system which includes full automation and walk-away capability.

From Fluxion Biosciences 27 Jan 2010

Antibiotics may be effective in fighting MRSA infections

Researchers at the University of Illinois at Chicago and Israel's Weizman Institute of Science have found that two antibiotics working together might be more effective in fighting pathogenic bacteria than either drug on its own.

27 Jan 2010

Radiation therapy safe and effective for cancer treatment

In response to the issues raised by the Jan. 24 New York Times article, "Radiation Offers New Cures and Ways to Do Harm," US Oncology, Inc. wants to ensure that cancer patients and the general public understand that the benefits received from radiation therapy in cancer care far outweigh the risks, and that cancer patients fighting their disease with help from the US Oncology physician network, and their loved ones, can rest assured that extensive quality control measures are put in place to minimize risks.

27 Jan 2010

Applied Biosystems signs cross-licensing agreement with Idaho Technology

Applied Biosystems LLC, part of Life Technologies Corporation, and Idaho Technology, Inc. have signed a cross-licensing agreement which covers a broad range of products including hardware, software and reagents.

27 Jan 2010

Spectrum Pharmaceuticals to submit additional data for FUSILEV sNDA

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has met with the FDA regarding it’s supplemental New Drug Application (sNDA) for FUSILEV® (levoleucovorin) for injection for the treatment of patients with advanced metastatic colorectal cancer. In October 2009, the FDA issued a Complete Response letter regarding its sNDA for FUSILEV.

25 Jan 2010

Elan Drug Technologies issues statement on FDA approval of AMPYRA

Elan Drug Technologies, a business unit of Elan Corporation, plc (NYSE: ELN) today issued the following statement regarding the U.S. Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) as a treatment to improve walking in patients with multiple sclerosis (MS).

25 Jan 2010

Study of 16INK4A gene's role in progression of retinoblastoma

Retinoblastoma is a pediatric eye cancer initiated by the loss or mutation of both copies of the retinoblastoma gene. Current evidence suggests that additional genetic alterations are required for retinoblastoma to become fully malignant.

23 Jan 2010

Kane Biotech grants 175,000 stock options at $0.15 per common share

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms, announces today that it has granted an aggregate of 175,000 stock options at an exercise price of $0.15 per common share, to the President & CEO of the Company.

23 Jan 2010

Island Labs receives NHP approval for Stemcelex

Island Labs, a leader in natural dermatological products, has become the first company in Health Canada's history to receive Natural Health Product (NHP) approval.

23 Jan 2010

Pfizer's global R&D facilities to deploy ChemAxon's Markush platform

ChemAxon - a leading provider of cheminformatics software for the life sciences industry has entered into agreement with Pfizer to provide its Markush searching and structure enumeration functionality for global development and deployment within Pfizer's global R&D facilities.

23 Jan 2010